Abstract 98P
Background
We investigate whether the continuation of adjuvant treatment and clinical course of adjuvant treatment would be affected by the development of postoperative complications in the patients who underwent curative resection for colon cancer in a pooled analysis of two large phase III studies performed in Japan.
Methods
The study examined the patients who enrolled in 1303, phase III comparing the efficacy of 6 months and 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer patients and in 882, a phase III to confirm tolerability oxaliplatin, fluorouracil, and l-leucovorin in Japanese stage II/III colon cancer patients. In this study, POCs were defined as the following major surgical complication; Anastomotic leakage, Pneumonia, Bowel obstruction/ileus, Surgical site infection, Postoperative bleeding, Urinary tract infection, and Fistula. The patients were classified as those with POCs (C group) and those without POCs (NC group).
Results
2095 patients were examined in the present study. POCs were observed in 169 patients (8.1%). The overall survival rates at five-year after surgery was 75.3% in the C-group and 86.5% in NC-group, respectively (p=0.0017). Hazard ratio of POCs for OS was 1.77 (95% confidence interval, 1.23 to 2.54; p=0.0017). Time to adjuvant treatment failure (TTF) of adjuvant chemotherapy was almost similar; 6-months TTF was 68.6% in C-group and 67.1% in NC-group. Dose reduction rate of adjuvant chemotherapy and adjuvant treatment suspension rate were also similar between C-group and NC-group (45.0% vs 48.7%, p=0.3520 and 52.7% vs 55.0%, p=0.5522, respectively).
Conclusions
POCs were associated with the poor prognosis, while the POCs did not affect the intensity of adjuvant chemotherapy. These results suggested that the POCs itself have negative survival impact.
Clinical trial identification
Editorial acknowledgement
This study was supported, in part, by the non-profit organization Epidemiological & Clinical Research Information Network (ECRIN).
Legal entity responsible for the study
Japanese Foundation for Multidisciplinary Treatment of Cancer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract